The in-house performance for the card lot in question, 01-21201-50, did not identify any product deficiencies.The investigation focused on the in-house epoc performance for po2.Card lot 01-21201-50 was tested with arterialized blood and with aqueous control fluids eurotrol l1 and eurotrol l3 at the time of product release.Aqueous fluids and arterialized blood performed as expected and met product specifications at the time of release.In addition, there were no other complaints received on card 01-21201-50.Therefore, there is no evidence that the system or reagent cards are not performing as intended.Additionally, it was noted the customer was using earlobe capillary samples.The process of capillary collection may change po2 levels significantly and is susceptible to factors such as air contamination.According to clsi c46-a blood gas and ph analysis and related measurements: approved guideline, arterial blood samples are preferred for blood gas analysis.No comparative value was obtained after the patient received oxygen.Without a true value, there is not enough information to allege the epoc was not performing as it was intended.Patients with low oxygen saturation may encounter increased oxygen extraction, which could present as a lower venous or capillary sample than expected.Additionally, no comparative value was obtained for the po2 result prior to receiving oxygen so it is not possible to determine if that result was correct given the sample type used.There is not enough evidence that points to a systemic product problem and there are many variables introduced when capillary blood is used for blood gas analysis.It should also be noted that the customer's qc was out of range prior to patient analysis.The cause of the event is unknown.
|